Short Interest in CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Rises By 161.2%

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) was the recipient of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 138,254 shares, an increase of 161.2% from the May 14th total of 52,933 shares. Based on an average daily trading volume, of 1,432,012 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CSLLY. Zacks Research downgraded CSL from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Jefferies Financial Group downgraded CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Citigroup downgraded CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Finally, Canaccord Genuity Group downgraded CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Four analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Reduce”.

CSL Stock Performance

Shares of OTCMKTS CSLLY traded down $0.07 during trading on Friday, reaching $19.08. 247,197 shares of the stock traded hands, compared to its average volume of 444,235. CSL has a 52-week low of $16.01 and a 52-week high of $44.86. The company has a quick ratio of 1.15, a current ratio of 2.57 and a debt-to-equity ratio of 0.51. The company has a 50-day moving average of $20.77 and a 200-day moving average of $40.12.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.